WO2008016108A1 - Agent de prévention d'une infection - Google Patents
Agent de prévention d'une infection Download PDFInfo
- Publication number
- WO2008016108A1 WO2008016108A1 PCT/JP2007/065171 JP2007065171W WO2008016108A1 WO 2008016108 A1 WO2008016108 A1 WO 2008016108A1 JP 2007065171 W JP2007065171 W JP 2007065171W WO 2008016108 A1 WO2008016108 A1 WO 2008016108A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- influenza virus
- virus infection
- sphingomyelin
- fat globule
- globule membrane
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract description 20
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 64
- 239000012528 membrane Substances 0.000 claims abstract description 51
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 20
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims abstract description 18
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 230000009385 viral infection Effects 0.000 claims description 50
- 230000003449 preventive effect Effects 0.000 claims description 21
- 210000004379 membrane Anatomy 0.000 description 48
- 235000019197 fats Nutrition 0.000 description 42
- 239000003795 chemical substances by application Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 235000013336 milk Nutrition 0.000 description 16
- 239000008267 milk Substances 0.000 description 16
- 210000004080 milk Anatomy 0.000 description 16
- 241000700605 Viruses Species 0.000 description 15
- 235000014121 butter Nutrition 0.000 description 14
- 239000006071 cream Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 235000015155 buttermilk Nutrition 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000002265 prevention Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000000108 ultra-filtration Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 7
- 239000002994 raw material Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 235000019784 crude fat Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000021243 milk fat Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 108010071421 milk fat globule Proteins 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241000285721 Ibaraki virus Species 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 235000015197 apple juice Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- STVYPZZQOXPZBX-UHFFFAOYSA-N ethanol;hexane;hydrate Chemical compound O.CCO.CCCCCC STVYPZZQOXPZBX-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000020958 lipid digestion Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- -1 sphingomyelin Chemical compound 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Definitions
- the present invention relates to an influenza virus infection preventive agent comprising a fat globule membrane component as an active ingredient.
- the present invention also relates to a preventive agent for influenza virus infection comprising a phospholipid having sphingosine and / or a derivative thereof, particularly sphingomyelin as an active ingredient.
- type A viruses There are three types of influenza viruses, type A, type B, and type C. Of these, type A viruses are susceptible to mutations and soon to cause a global pandemic. Prevention of influenza virus infection is mainly done by vaccination. However, because influenza viruses are prone to mutations such as antigen shifts and antigen drifts, the prevention effect of vaccines that are often inconsistent with the prevalent virus and vaccine antigens is not satisfactory. Currently.
- An object of the present invention is to provide a preventive agent for influenza virus infection that can be safely taken on a daily basis.
- the present inventors have paid attention to milk components having various physiological activities and conducted extensive research on the infection prevention effect of influenza virus. As a result, fat globule membrane components and phospholipids having sphingosin and / or The derivative has been found to be effective in preventing influenza virus infection, and the present invention has been completed.
- the present invention comprises the following.
- Influenza virus infection preventive agent containing fat globule membrane component as an active ingredient.
- a preventive agent for influenza virus infection which comprises a phospholipid having sphingosin and / or a derivative thereof as an active ingredient.
- a food or drink for preventing influenza virus infection which contains a phospholipid having sphingosine and / or a derivative thereof.
- influenza virus infection preventive agent and the food and drink for preventing influenza virus infection according to the present invention can prevent influenza virus infection.
- influenza virus infection preventive agent and the food and drink for preventing influenza virus infection of the present invention contain fat globule membrane components as active ingredients, they can be supplied in large quantities at a relatively low cost, and are extremely safe. High! /, And! /, Have features! /, Ru.
- influenza virus infection preventive agent and the influenza virus infection-preventing food and drink of the present invention contain phospholipids and / or derivatives thereof, particularly sphingomyelin, as active ingredients, they are relatively inexpensive. It can be supplied in large quantities, and is extremely safe! /, And! /.
- the present invention relates to an influenza virus infection preventive agent comprising a fat globule membrane component as an active ingredient
- the present invention relates to foods and drinks that contain a fat globule membrane component and have been provided with an action to prevent influenza virus infection.
- the fat globule membrane component is a film that coats milk fat globules secreted from the mammary gland and has not only a function of dispersing fat in milk but also a lot of physiological as food for newborn animals. It has a function.
- the milk fat globule membrane of milk is composed of about 45% by mass protein and about 55% by mass lipid, and contains a high-molecular glycoprotein called milk mucin as protein.
- lipid including triacylglycerols about 70 weight 0/0, phospholipids about 27 wt%, about 3 wt% such as cholesterol.
- Milk fat globule membrane of milk is known to have functions such as protection of milk fat globules, stabilization of milk fat emulsion, promotion of digestion of lipids, and protection against infection with specific bacteria.
- mucins containing a high amount of sialic acid isolated from animal mucosal tissues have anti-influenza virus activity (Biochem. J., 277, 713-718, 1991).
- milk fat globule membrane components are completely different in composition.
- the fat globule film component used in the present invention is obtained, for example, when a butter granule is produced by treating a cream obtained by centrifugal separation of milk of a mammal such as ushi with churn or the like. Buttermilk can be used as is!
- the non-fat milk component was removed by repeating the operation of adding the same amount of water to the cream described above, mixing, and centrifuging to prepare a cream having the original fat percentage several times.
- the cream may be treated with churn to produce butter granules, and the resulting butter milk may be used as a fat globule membrane component.
- butter serum obtained as a residue when heating the above-mentioned butter granules and producing butter oil by centrifugation may be used as a fat globule membrane component.
- these buttermilk and buttersarum contain a sufficient amount of fat globule membrane components! Therefore, these buttermilk and buttersarum are used as fat globule membrane components.
- These buttermilk and butterserum can be further dialyzed, ammonium sulfate fraction, gel filtration, isoelectric precipitation, ion exchange chromatography, solvent fractionation, ultrafiltration (UF), and precision Purified by methods such as filtration (MF), purity of fat globule membrane components May be used with a higher value.
- a separation and filtration technique using a UF membrane or MF membrane can be used.
- the lipid fraction cannot penetrate UF and MF membranes and can remove proteins, lactose and minerals.
- the fractional molecular weight of the UF membrane and the pore size of the MF membrane are not so strict, and those skilled in the art can set appropriate values based on experiments.
- the pore size is 1.2 m or less, preferably 0.2 111 or less
- the molecular weight cutoff is preferably 10,000 or more, preferably (or 50,000-100,000). It is a guide.
- the filtered concentrated solution may be spray-dried to obtain a composition having a high fat globule membrane component content, or after homogenization (100 kg / cm 2 or more) of the concentrated solution treated with UF membrane or MF membrane, Alternatively, the composition may be UF-treated and spray-dried to further increase the fat globule film component content.
- the crude fraction of the fat globule membrane component can be obtained, for example, as follows. Compositions with increased fat globule membrane component content are combined with polar solvents such as ethanol and methanol, and combinations of nonpolar and polar solvents such as ether ethanol (1: 3 v / v), black-form form-methanol (2 : Lv / v), treatment with black mouth form / methanol / water (1: 2: 0.8 v / v), etc. to extract crude fat. This crude fat can be fractionated with acetone to obtain an acetone-insoluble fraction rich in fat globule membrane components.
- polar solvents such as ethanol and methanol
- nonpolar solvents such as ether ethanol (1: 3 v / v)
- black-form form-methanol (2 : Lv / v) black-form form-methanol (2 : Lv / v)
- black mouth form / methanol / water (1: 2: 0.8 v /
- butter serum which is a residue of butter oil prepared from cream
- butter serum is rich in fat globule membrane components and is one of the preferred raw materials.
- a crude fat extracted from this butter serum with ethanol and the crude fat fractionated with acetone may be used.
- an extract fraction of a mixed solvent of hexane-ethanol-water Japanese Patent Laid-Open No. 7-173182
- commercially available milk-derived fat globule membrane components may be used.
- the amount of the fat globule membrane component in the influenza virus infection preventive agent and the food and drink for preventing influenza virus infection of the present invention is about 0.1 mg to 5000 mg per day for fat globule membrane components in the case of adults. What is necessary is just to adjust the compounding quantity of a fat globule membrane component so that it may do. Within this range, the ability to prevent influenza virus infection can be achieved. It is an active ingredient of the influenza virus infection preventive agent of the present invention. Since the fat globule membrane component is a milk component, its safety is completely a problem even if it is consumed in large quantities!
- the present invention also relates to a phosphatide and / or derivative thereof having sphingosine, particularly an influenza virus infection preventive agent comprising sphingomyelin as an active ingredient, and a phospholipid having sphingosin and / or a derivative thereof, particularly sphingosine. It relates to foods and drinks that contain ingomyelin and have been given the effect of preventing influenza virus infection.
- anti-inflammatory analgesic topical agents lipid digestion / absorption function improving agents, therapeutic agents for intestinal motility dysfunction (JP-A-5-186330, JP-A-11 269074, No. 2003-252765)) is not known at all, and is not used for the prevention of influenza virus infection! /, Na! /, .
- Japanese Patent Publication No. 2006-508045 Japanese Patent Publication No. 2006-508045
- Japanese Patent Laid-Open No. 5-339169 Japanese Patent Laid-Open No. 5-339169
- sialic acid which is a force component that is known to have anti-influenza activity
- Gandarioside which is a glycolipid contained in milk.
- Glycolipids containing sialic acid are functions expressed by a mechanism that antagonistically inhibits the binding between virus and mucosal epithelial cells. Therefore, it is clear that it does not recall the function of sphingomyelin without sialic acid.
- Phospholipids having sphingosine and / or derivatives thereof, particularly sphingomyelin, used in the present invention may be purified or used as sphingomyelin-containing phospholipids.
- sphingomyelin is contained in a large amount in animal brain and milk fat, it is preferably derived from milk in the practice of the present invention.
- raw milk should be made from whey protein concentrate (WPC), etc.!
- a phospholipid fraction containing sphingomyelin such as raw milk and WPC
- extraction with ether or acetone JP-A-3-47192
- Examples of known methods such as a method using a water-soluble fraction containing butter card or butter serum are available.
- the sphingomyelin content of the fractions obtained by adopting these raw materials and methods is about 28% by mass and about 9% by mass, respectively.
- the sphingomyelin-containing phospholipid fraction is dialyzed, ammonium sulfate fraction, gel filtration, isoelectric precipitation, ion exchange chromatography, solvent fractionation, ultrafiltration (UF), and microfiltration ( Sfingomyelin with increased purity can be obtained by purification using a method such as MF).
- sphingomyelin and sphingomyelin-containing phospholipids can be appropriately in the form of a liquid, powder, tablet or the like and can be directly orally administered.
- the phospholipid composition contains an effective amount of phosphatidylcholine as specified in human nutrition requirements!
- the amount of the phospholipid having sphingosin and / or a derivative thereof in the influenza virus infection preventive agent and the food and drink for preventing influenza virus infection of the present invention includes phospholipid having sphingosin and / or The amount of the derivative, especially sphingomyelin, may be adjusted so that about 0.1 mg to 5000 mg per day can be ingested. Within this range, the ability to prevent influenza virus infection can be achieved. Since the phospholipid having sphingosin, particularly sphingomyelin, which is an active ingredient of the influenza virus infection preventive agent of the present invention, is a milk component, it can be said that its safety is not a problem even when a large amount is consumed. .
- Examples of the dosage form of the influenza virus infection preventive agent of the present invention include tablets, capsules, granules, powders, powders, and liquids. These may be administered orally or nasally. Moreover, these dosage forms can be produced by a conventionally known ordinary method. For example, carriers acceptable for formulation production, It is mixed with a form and molded.
- Example 1
- Influenza virus PR8 H1N1
- the fat globule membrane component obtained in Example 2 was orally administered, and the infection prevention effect was determined by the virus titer in the nasal lavage fluid 3 days after the virus infection.
- the fat globule membrane component was used after dissolving the powder in distilled water. The plaque method using MDCK cells was used for the determination.
- Raw materials were mixed according to the formulation shown in Table 2, granulated, and then filled into capsules to produce capsules for preventing influenza virus infection.
- Raw materials were mixed according to the formulation shown in Table 3, filled into containers, and then heat sterilized to produce a drink for preventing influenza virus infection.
- a reaction solution obtained by allowing protease to act on a 10% by mass aqueous solution of whey protein concentrate (WPC) was extracted with a Kuroguchi form-methanol (2: 1) solution, concentrated, and further extracted with acetone.
- WPC whey protein concentrate
- a complex lipid fraction was obtained.
- this complex lipid fraction was subjected to fluorosilyl column chromatography and step-extracted with a chloroform-methanol solution to obtain a phospholipid fraction.
- This phospholipid fraction was subjected to silica gel chromatography, and step-extracted with a black mouth form-methanol solution was freeze-dried to obtain sphingomyelin.
- the sphingomyelin was subjected to thin-layer chromatography, and then developed with a Datemer reagent and measured by the densitometry method.
- the sphingomyelin content was 95.2 mass 0 /. Met.
- the sphingomyelin thus obtained can be used as it is as a preventive agent for influenza virus infection.
- influenza B virus As a virus, mice (Balb / c, male, 6 weeks old) were infected nasally with B / Ibaraki virus, and at the same time, the sphingomyelin (SPM) ⁇ g / ml solution obtained in Example 1 was 5 1 / nasal cavity. Intranasal administration (dosage: 0. Nasal administration and the influenza virus infection prevention effect was determined by the virus titer in the nasal lavage fluid. In addition, as a control, each nasal infection group of each influenza virus was used as a control. The plaque method using MDCK cells was used for the determination.
- SPM sphingomyelin
- Influenza virus PR8 (H1N1) was infected to mice (Balb / c, male, 6 weeks old) with a viral load of 1 X lCTpfu. Prior to infection treatment, sphingomyelin was orally administered, and the infection prevention effect was determined by the virus titer in the nasal lavage fluid 3 days after virus infection. Sphingomyelin was dispersed in water for oral administration. The plaque method using MDCK cells was used for the determination.
- Example 7 5 g of sphingomyelin obtained in Example 7 was dissolved in 200 ml of distilled water for injection to produce a solution for intranasal spray.
- Raw materials were mixed according to the formulation shown in Table 6, granulated, and then filled into capsules to produce capsules for preventing influenza virus infection.
- Raw materials were mixed according to the formulation shown in Table 7, filled into containers, and then heat sterilized to produce a drink for preventing influenza virus infection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Polymers & Plastics (AREA)
- Otolaryngology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007279674A AU2007279674B2 (en) | 2006-08-04 | 2007-08-02 | Agent for preventing infection |
CA2660120A CA2660120C (en) | 2006-08-04 | 2007-08-02 | Agent for preventing infection |
EP07805892A EP2047856A4 (en) | 2006-08-04 | 2007-08-02 | AGENT FOR PREVENTING INFECTION |
CN200780029115.1A CN101505767B (zh) | 2006-08-04 | 2007-08-02 | 预防感染的药剂 |
US12/376,251 US20090312291A1 (en) | 2006-08-04 | 2007-08-02 | Agent for preventing infection |
KR1020097002329A KR101250323B1 (ko) | 2006-08-04 | 2007-08-02 | 감염 예방제 |
US13/544,748 US20120277187A1 (en) | 2006-08-04 | 2012-07-09 | Agent for Preventing Infection |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-213276 | 2006-08-04 | ||
JP2006213276A JP2008037789A (ja) | 2006-08-04 | 2006-08-04 | 感染予防剤 |
JP2006213273A JP5202827B2 (ja) | 2006-08-04 | 2006-08-04 | 感染予防剤 |
JP2006-213273 | 2006-08-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/544,748 Division US20120277187A1 (en) | 2006-08-04 | 2012-07-09 | Agent for Preventing Infection |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008016108A1 true WO2008016108A1 (fr) | 2008-02-07 |
Family
ID=38997282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/065171 WO2008016108A1 (fr) | 2006-08-04 | 2007-08-02 | Agent de prévention d'une infection |
Country Status (7)
Country | Link |
---|---|
US (2) | US20090312291A1 (ja) |
EP (2) | EP2335705B1 (ja) |
KR (1) | KR101250323B1 (ja) |
AU (1) | AU2007279674B2 (ja) |
CA (1) | CA2660120C (ja) |
ES (1) | ES2444501T3 (ja) |
WO (1) | WO2008016108A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008093657A1 (ja) * | 2007-01-30 | 2008-08-07 | Snow Brand Milk Products Co., Ltd. | 美肌剤 |
JP2009190994A (ja) * | 2008-02-13 | 2009-08-27 | Kitasato Institute | 抗インフルエンザウイルス剤、及びその有効成分の製造方法 |
JP2010059155A (ja) * | 2008-08-07 | 2010-03-18 | Kao Corp | 運動機能向上剤 |
WO2010134384A1 (ja) * | 2009-05-20 | 2010-11-25 | よつ葉乳業株式会社 | 皮膚機能改善組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012166859A2 (en) * | 2011-06-01 | 2012-12-06 | The Curators Of The University Of Missouri | Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections |
SE537951C2 (sv) * | 2013-07-01 | 2015-12-01 | Hero Ag | Profylaktisk användning av modersmjölksersättning mot otit |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0347192A (ja) | 1989-04-25 | 1991-02-28 | Snow Brand Milk Prod Co Ltd | 乳または乳製品由来のリン脂質画分を分画精製する方法 |
JPH04105616A (ja) | 1990-08-24 | 1992-04-07 | Asahi Chem Ind Co Ltd | 加熱機能を有する飲食品封入体の製造方法 |
JPH0530942A (ja) * | 1991-07-25 | 1993-02-09 | Riyoushiyoku Kenkyukai | 高分子の腸管透過性を制御する効果のある 飲食品及び医薬品 |
JPH05186330A (ja) | 1991-11-12 | 1993-07-27 | Pola Chem Ind Inc | 消炎鎮痛外用剤 |
JPH05339161A (ja) * | 1991-03-07 | 1993-12-21 | Yakult Honsha Co Ltd | IgA産生促進剤及びIgA産生促進飲食品 |
JPH05339169A (ja) | 1992-03-03 | 1993-12-21 | Dai Ichi Seiyaku Co Ltd | 経口ワクチン |
JPH07173182A (ja) | 1993-12-17 | 1995-07-11 | Meiji Milk Prod Co Ltd | リン脂質を主成分とする乳由来の極性脂質の抽出方法及び濃縮方法 |
JPH11269074A (ja) | 1998-03-18 | 1999-10-05 | Snow Brand Milk Prod Co Ltd | 脂質の消化吸収機能改善剤 |
JP2001233773A (ja) * | 2000-02-22 | 2001-08-28 | Toko Yakuhin Kogyo Kk | 抗ウイルス剤 |
JP2001275614A (ja) * | 2000-03-30 | 2001-10-09 | Meiji Milk Prod Co Ltd | 哺乳動物の乳由来のリン脂質含有経口性組成物 |
JP2003252765A (ja) | 2002-02-28 | 2003-09-10 | Snow Brand Milk Prod Co Ltd | 腸管運動機能不全性疾患の治療剤 |
WO2005019438A1 (ja) * | 2003-08-21 | 2005-03-03 | Otsuka Pharmaceutical Co., Ltd. | 粘膜免疫賦活作用を有する乳酸菌 |
JP2006508045A (ja) | 2002-07-30 | 2006-03-09 | エスペリオン セラピューティクス,インコーポレイテッド | ヒト以外の動物のアポリポプロテインa−iタンパク質の使用方法 |
JP2006213276A (ja) | 2005-02-07 | 2006-08-17 | Nissan Motor Co Ltd | 運転意図推定装置、車両用運転操作補助装置および車両用運転操作補助装置を備えた車両 |
JP2006213273A (ja) | 2005-02-07 | 2006-08-17 | Toyota Motor Corp | 電源制御装置 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448469B1 (en) * | 1991-10-02 | 2002-09-10 | Genzyme Corporation | Production of membrane proteins in the milk of transgenic nonhuman mammals |
JP3042738B2 (ja) * | 1992-03-31 | 2000-05-22 | 雪印乳業株式会社 | ガングリオシドgm3組成物及びその製造法 |
SE501697C2 (sv) * | 1993-02-11 | 1995-04-24 | Svenska Mejeriernas Riksforeni | Förfarande för utvinning av sfingomyelin |
CA2320117A1 (en) * | 1998-02-12 | 1999-08-19 | Emory University | Sphingolipid derivatives and their methods of use |
JP2005281257A (ja) * | 2004-03-30 | 2005-10-13 | Snow Brand Milk Prod Co Ltd | 美肌剤 |
AU2005231622B2 (en) * | 2004-04-08 | 2011-05-26 | Jadolabs Gmbh | Tripartite conjugates containing a structure interacting with cell membrane rafts and their use |
JP4965063B2 (ja) * | 2004-05-07 | 2012-07-04 | 雪印メグミルク株式会社 | 口腔内細菌叢改善剤、抗菌剤及び生育促進剤。 |
EP1750673B1 (en) * | 2004-05-17 | 2009-12-02 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
-
2007
- 2007-08-02 EP EP11001424.8A patent/EP2335705B1/en not_active Not-in-force
- 2007-08-02 CA CA2660120A patent/CA2660120C/en not_active Expired - Fee Related
- 2007-08-02 EP EP07805892A patent/EP2047856A4/en not_active Withdrawn
- 2007-08-02 ES ES11001424.8T patent/ES2444501T3/es active Active
- 2007-08-02 US US12/376,251 patent/US20090312291A1/en not_active Abandoned
- 2007-08-02 AU AU2007279674A patent/AU2007279674B2/en not_active Ceased
- 2007-08-02 KR KR1020097002329A patent/KR101250323B1/ko active IP Right Grant
- 2007-08-02 WO PCT/JP2007/065171 patent/WO2008016108A1/ja active Application Filing
-
2012
- 2012-07-09 US US13/544,748 patent/US20120277187A1/en not_active Abandoned
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0347192A (ja) | 1989-04-25 | 1991-02-28 | Snow Brand Milk Prod Co Ltd | 乳または乳製品由来のリン脂質画分を分画精製する方法 |
JPH04105616A (ja) | 1990-08-24 | 1992-04-07 | Asahi Chem Ind Co Ltd | 加熱機能を有する飲食品封入体の製造方法 |
JPH05339161A (ja) * | 1991-03-07 | 1993-12-21 | Yakult Honsha Co Ltd | IgA産生促進剤及びIgA産生促進飲食品 |
JPH0530942A (ja) * | 1991-07-25 | 1993-02-09 | Riyoushiyoku Kenkyukai | 高分子の腸管透過性を制御する効果のある 飲食品及び医薬品 |
JPH05186330A (ja) | 1991-11-12 | 1993-07-27 | Pola Chem Ind Inc | 消炎鎮痛外用剤 |
JPH05339169A (ja) | 1992-03-03 | 1993-12-21 | Dai Ichi Seiyaku Co Ltd | 経口ワクチン |
JPH07173182A (ja) | 1993-12-17 | 1995-07-11 | Meiji Milk Prod Co Ltd | リン脂質を主成分とする乳由来の極性脂質の抽出方法及び濃縮方法 |
JPH11269074A (ja) | 1998-03-18 | 1999-10-05 | Snow Brand Milk Prod Co Ltd | 脂質の消化吸収機能改善剤 |
JP2001233773A (ja) * | 2000-02-22 | 2001-08-28 | Toko Yakuhin Kogyo Kk | 抗ウイルス剤 |
JP2001275614A (ja) * | 2000-03-30 | 2001-10-09 | Meiji Milk Prod Co Ltd | 哺乳動物の乳由来のリン脂質含有経口性組成物 |
JP2003252765A (ja) | 2002-02-28 | 2003-09-10 | Snow Brand Milk Prod Co Ltd | 腸管運動機能不全性疾患の治療剤 |
JP2006508045A (ja) | 2002-07-30 | 2006-03-09 | エスペリオン セラピューティクス,インコーポレイテッド | ヒト以外の動物のアポリポプロテインa−iタンパク質の使用方法 |
WO2005019438A1 (ja) * | 2003-08-21 | 2005-03-03 | Otsuka Pharmaceutical Co., Ltd. | 粘膜免疫賦活作用を有する乳酸菌 |
JP2006213276A (ja) | 2005-02-07 | 2006-08-17 | Nissan Motor Co Ltd | 運転意図推定装置、車両用運転操作補助装置および車両用運転操作補助装置を備えた車両 |
JP2006213273A (ja) | 2005-02-07 | 2006-08-17 | Toyota Motor Corp | 電源制御装置 |
Non-Patent Citations (4)
Title |
---|
BIOCHEM. J., vol. 277, 1991, pages 713 - 718 |
HIDARI K. ET AL.: "Sphingo Shishitsu Gosei Sogaizai ni yoru Influenza Virus Kansen eno Eikyo", SEIKAGAKU, DAI 65 KAI THE JAPANESE BIOCHEMICAL SOCIETY CHUBU SHIBU REIKAI SHOROKU, vol. 73, no. 12, 25 December 2001 (2001-12-25), pages 1474, XP003021034 * |
SCHEIFFELE P. ET AL.: "Influenza viruses select ordered lipid domains during budding from the plasma membrane", J BIOL CHEM., vol. 274, no. 4, 1999, pages 2038 - 2044, XP003021035 * |
See also references of EP2047856A4 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008093657A1 (ja) * | 2007-01-30 | 2008-08-07 | Snow Brand Milk Products Co., Ltd. | 美肌剤 |
JP2009190994A (ja) * | 2008-02-13 | 2009-08-27 | Kitasato Institute | 抗インフルエンザウイルス剤、及びその有効成分の製造方法 |
JP2010059155A (ja) * | 2008-08-07 | 2010-03-18 | Kao Corp | 運動機能向上剤 |
JP2014141496A (ja) * | 2008-08-07 | 2014-08-07 | Kao Corp | 運動機能向上剤 |
JP2016104805A (ja) * | 2008-08-07 | 2016-06-09 | 花王株式会社 | 運動機能向上剤 |
WO2010134384A1 (ja) * | 2009-05-20 | 2010-11-25 | よつ葉乳業株式会社 | 皮膚機能改善組成物 |
JPWO2010134384A1 (ja) * | 2009-05-20 | 2012-11-08 | よつ葉乳業株式会社 | 皮膚機能改善組成物 |
JP5679966B2 (ja) * | 2009-05-20 | 2015-03-04 | よつ葉乳業株式会社 | 皮膚機能改善組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20090312291A1 (en) | 2009-12-17 |
KR20090038446A (ko) | 2009-04-20 |
CA2660120A1 (en) | 2008-02-07 |
ES2444501T3 (es) | 2014-02-25 |
EP2335705B1 (en) | 2013-12-18 |
AU2007279674A1 (en) | 2008-02-07 |
EP2047856A1 (en) | 2009-04-15 |
US20120277187A1 (en) | 2012-11-01 |
KR101250323B1 (ko) | 2013-04-03 |
EP2335705A1 (en) | 2011-06-22 |
CA2660120C (en) | 2016-04-05 |
AU2007279674B2 (en) | 2013-10-03 |
EP2047856A4 (en) | 2010-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2653765C (en) | Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level | |
WO2008016108A1 (fr) | Agent de prévention d'une infection | |
JP2007089535A (ja) | 乳由来複合脂質高含有粉末 | |
JP5465834B2 (ja) | 肝機能保護剤 | |
JPH11269074A (ja) | 脂質の消化吸収機能改善剤 | |
TW200916093A (en) | Treating or preventing rotavirus infection | |
JP5202827B2 (ja) | 感染予防剤 | |
JP2016535734A (ja) | コリン及びその誘導体を含む組成物、その用途及び調製方法 | |
JP4958339B2 (ja) | 脂質代謝改善剤 | |
JP7025112B2 (ja) | Bdnf産生促進剤 | |
WO2017221845A1 (ja) | 血流改善剤、ローヤルゼリー組成物及びローヤルゼリー組成物の製造方法 | |
JP2008037789A (ja) | 感染予防剤 | |
TWI646969B (zh) | 乳凝集素及/或其分解物之用途 | |
JP2008038011A (ja) | 高純度リン脂質の製造法 | |
JP2002255824A (ja) | 免疫賦活組成物 | |
JP2003300890A (ja) | 血中トリグリセリド濃度低下剤 | |
JP4034364B2 (ja) | 抗アレルギー剤 | |
JP2016138058A (ja) | 肩こり改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780029115.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07805892 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12376251 Country of ref document: US Ref document number: 2007279674 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2660120 Country of ref document: CA Ref document number: 1020097002329 Country of ref document: KR Ref document number: 2007805892 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007279674 Country of ref document: AU Date of ref document: 20070802 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: RU |